Treatment considerations in women with schizophrenia

Journal of Women's Health

Volumn 15, Issue 10, 2006, Pages 1132-1140

  Kelly, Deanna L ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; CARBAMAZEPINE; CHLORPROMAZINE; CLOZAPINE; CYTOCHROME P450 1A2; CYTOCHROME P450 2D6; FLUPHENAZINE; HALOPERIDOL; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; ORAL CONTRACEPTIVE AGENT; PHENOTHIAZINE; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; THIORIDAZINE; ZIPRASIDONE;

ALCOHOLISM; AMENORRHEA; ANHEDONIA; ARTICLE; BLUNTED AFFECT; BRADYCARDIA; CARDIOVASCULAR DISEASE; CHRONIC DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE DEFECT; DELUSIONAL DISORDER; DIABETES MELLITUS; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG METABOLISM; DRUG POTENTIATION; DRUG TISSUE LEVEL; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; FEMALE; FETUS DISEASE; GALACTORRHEA; GASTROINTESTINAL SYMPTOM; HALLUCINATION; HEALTH STATUS; HEART DISEASE; HUMAN; HUMAN RELATION; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERPROLACTINEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPOTHYROIDISM; LOW BIRTH WEIGHT; LOW DRUG DOSE; MALE; MEDICAL CARE; MENTAL DISEASE; META ANALYSIS; METABOLIC DISORDER; MONOTHERAPY; MOOD DISORDER; NEGATIVE SYNDROME; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; ONSET AGE; PATIENT COUNSELING; POPULATION RESEARCH; PRIORITY JOURNAL; QT PROLONGATION; SCHIZOPHRENIA; SEX DIFFERENCE; SEXUAL DYSFUNCTION; SEXUALITY; SIDE EFFECT; SOCIAL PSYCHOLOGY; SOCIETY; SOMNOLENCE; SPEECH DISORDER; SPONTANEOUS ABORTION; STILLBIRTH; SYMPTOMATOLOGY; SYSTEMATIC REVIEW; TARDIVE DYSKINESIA; THOUGHT DISORDER; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; EVIDENCE-BASED MEDICINE; FEMALE; HEALTH SERVICES NEEDS AND DEMAND; HUMANS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; WOMEN'S HEALTH; WOMEN'S HEALTH SERVICES;

EID: 33846471948     PISSN: 15409996     EISSN: None     Source Type: Journal    
DOI: 10.1089/jwh.2006.15.1132     Document Type: Article

References (79)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders DSM-IV-TR (text revision), 4th ed. Washington, DC: American Psychiatric Association; 2000:312.
2. Leung A, Chue P. Sex differences in schizophrenia: A review of the literature. Acta Psychiatr Scand 2001;401(Suppl):3.
3. Timms D. Gender, social mobility and psychiatric diagnoses. Soc Sci Med 1998;46:1235.
4. Murray RM, Van Os J. Predictors of outcome in schizophrenia. J Clin Psychopharmacol 1998;18(Suppl 1):2S.
5. Salokangas RK, Honkonen T, Stengard E, Koivisto AM. Symptom dimensions and their association with outcome and treatment setting in long-term schizophrenia. Results of the DSP project. Nord J Psychiatry 2002;56:319.
6. Gur RE, Turetsky BI, Cowell PE, et al. Temporolimbic volume reductions in schizophrenia. Arch Gen Psychiatry 2000;57:769.
7. Bullmore E, Brammer M, Harvey I, Murray R, Ron M. Cerebral hemispheric asymmetry revisited: Effects of handedness, gender and schizophrenia measured by radius of gyration in magnetic resonance images. Psychol Med 1995;25:349.
8. Alexander RC, Mukherjee S, Richter J, Kaufmann CA. Minor physical anomalies in schizophrenia. J Nerv Ment Dis 1994;182:639.
9. Szymanski S, Lieberman JA, Alvir JM, et al. Gender differences in onset of illness, treatment response, cause and biologic indexes in first-episode schizophrenia patients. Am J Psychiatry 1995;152:698.
10. Angermeyer MC, Kuhn L, Goldstein JM. Gender and the course of schizophrenia: Differences in treated outcomes. Schizophr Bull 1990;16:293.
11. Andreasen NC, Swayze VW 2nd, Flaum M, Yates WR, Arndt S, McChesney C. Ventricular enlargement in schizophrenia evaluated with computed tomographic scanning. Effects of gender, age, and stage of illness. Arch Gen Psychiatry 1990;47:1008.
12. Ragland JD, Gur RE, Klimas BC, McGrady N, Gur RC. Neuropsychological laterality indices of schizophrenia: Interactions with gender. Schizophr Bull 1999; 25:79.
13. Lewine RR, Walker EF, Shurett R, Caudle J, Haden C. Sex differences in neuropsychological functioning among schizophrenic patients. Am J Psychiatry 1996; 153:1178.
14. Danielsson K, Flyckt L, Edman G. Sex differences in schizophrenia as seen in the Rorschach test. Nord J Psychiatry 2001;55:137.
15. Goldberg SC, Schooler NR, Davidson EM, Kayce MM. Sex and race differences in response to drug treatment among schizophrenia. Psychopharmacologia 1966; 9:31.
16. Seeman MV. Gender differences in schizophrenia. Can J Psychiatry 1982;27:107.
17. Yonkers KA, Kando JC, Cole JO, Blumenthal S. Gender differences in pharmacokinetics and pharmacodynamics of psychotropic medication. Am J Psychiatry 1992;149:587.
18. Pinals DA, Malhotra AK, Missar CD, Pickar D, Breier A. Lack of gender differences in neuroleptic response in patients with schizophrenia. Schizophr Res 1996; 22:215.
19. Robinson DG, Woerner MG, Alvir JM, et al. Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry 1999;156:544.
20. Labelle A, Light M, Dunbar F. Risperidone treatment of outpatients with schizophrenia: No evidence of sex differences in treatment response. Can J Psychiatry 2001;46:534.
21. Goldstein JM, Cohen LS, Horton NJ, et al. Sex differences in clinical response to olanzapine compared with haloperidol. Psychiatry Res 2002;110:27.
22. Pollock BG. Gender differences in psychotropic drug metabolism. Psychopharmacol Bull 1997;33:235.
23. Kelly DL, Conley RR, Tamminga CA. Differential olanzapine plasma concentrations by sex in a fixed-dose study. Schizophr Res 1999;40:101.
24. Lane HY, Chang YC, Chang WH, Lin SK, Tseng YT, Jann MW. Effects of gender and age on plasma levels of clozapine and its metabolites: Analyzed by critical statistics. J Clin Psychiatry 1999;60:36.
25. Carrillo JA, Herraiz AG, Ramos SI, Gervasini G, Vizcaino S, Benitez J. Role of the smoking-induced cytochrome (CYP)1A2 and polymorphic CY2D6 in steady-state concentrations of olanzapine. J Clin Psychopharmacol 2003;23:119.
26. Yukawa E, Ichimaru R, Maki T, et al. Interindividual variation of serum haloperidol concentrations in Japanese patients - Clinical considerations on steady-state serum level-dose ratios. J Clin Pharm Ther 2003;28:97.
27. Linnet K, Olesen OV. Free and glucuronidated olanzapine serum concentrations in psychiatric patients: Influence of carbamazepine comedication. Ther Drug Monit 2002;24:512.
28. Balant-Gorgia AE, Gex-Fabry M, Genet C, Balant LP. Therapeutic drug monitoring of risperidone using a new, rapid HPLC method: Reappraisal of interindividual variability factors. Ther Drug Monit 1999; 21:105.
29. Seeman MV. Gender differences in the prescribing of antipsychotic drugs. Am J Psychiatry 2004;161:1324.
30. Rademaker M. Do women have more adverse drug reactions? Am J Clin Dermatol 2001;2:349.
31. Casey D. Neuroleptic drug-induced extrapyramidal syndromes and tardive dyskinesia. Schizophr Res 1991;4:109.
32. Yassa R, Jeste D. Gender differences in tardive dyskinesia: A critical review of the literature. Schizophr Bull 1992;18:701.
33. Allison DB, Casey DE. Antipsychotic-induced weight gain: A review of the literature. J Clin Psychiatry 2001;62(Suppl 7):22.
34. Basu A, Meltzer HY. Differential trends in prevalence of diabetes and unrelated general medical illness for schizophrenia patients before and after the atypical antipsychotic era. Schizophr Res 2006; epub ahead of print.
35. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004;27:596.
36. Kelly DL, Love RC. Ziprasidone and the QTc interval: Pharmacokinetic and pharmacodynamic considerations. Psychopharmacol Bull 2001;35:66.
37. Kuruvilla A, Peedicayil J, Srikrishna G, Kuruvilla K, Kanagasabapathy AS. A study of serum prolactin levels in schizophrenia: Comparison of males and females. Clin Exp Pharmacol Physiol 1992;19:603.
38. Wieck A, Haddad PM. Antipsychotic-induced hyperprolactinaemia in women: Pathophysiology, severity and consequences. Selective literature review. Br J Psychiatry 2003;182:199.
39. Becker D, Liver O, Mester R, Rapoport M, Weizman A, Weiss M. Risperidone, but not olanzapine, decreases bone mineral density in female premenopausal schizophrenia patients. J Clin Psychiatry 2003;64: 761.
40. Abraham G, Paing WW, Kaminski J, Joseph A, Kohegyi E, Josiassen RC. Effects of elevated serum prolactin on bone mineral density and bone metabolism in female patients with schizophrenia: A prospective study. Am J Psychiatry 2003;160:1618.
41. Simons JS, Carey MP. Prevalence of sexual dysfunctions: Results from a decade of research. Arch Sex Behav 2001;30:177.
42. Bengtsson-Tops A, Hansson L. Clinical and social needs of schizophrenic outpatients living in the community: The relationship between needs and subjective quality of life. Soc Psychiatry Psychiatr Epidemiol 1999;34:513.
43. McCann E. The expression of sexuality in people with psychosis: Breaking the taboos. J Adv Nurs 2000;32: 132.
44. Lukoff D, Gioia-Hasick D, Sullivan G, Golden JS, Nuechterlein KH. Sex education and rehabilitation with schizophrenic male outpatients. Schizophr Bull 1986;12:669.
45. Buddeberg C, Furrer H, Limacher B. Sexual problems in schizophrenic patients treated by ambulatory care. Psychiatr Prax 1988;15:187.
46. Miller LJ, Finnerty M. Family planning knowledge, attitudes and practices in women with schizophrenic spectrum disorders. J Psychosom Obstet Gynaecol 1998;19:210.
47. Miller LJ. Sexuality, reproduction, and family planning in women with schizophrenia. Schizophr Bull 1997;23:623.
48. Cournos F, Guido JR, Coomaraswamy S, Meyer-Bahlburg H, Sugden R, Horwath E. Sexual activity and risk of HIV infection among patients with schizophrenia. Am J Psychiatry 1994;151:228.
49. Gottesman II, Groome CS. HIV/AIDS risks as a consequence of schizophrenia. Schizophr Bull 1997; 23:675.
50. Otto-Salaj LL, Stevenson LY. Influence of psychiatric diagnoses and symptoms on HIV risk behavior in adults with serious mental illness. AIDS Read 2001;11:197.
51. Coverdale JH, Turbott S, Roberts H. Family planning needs and STD risk behaviours of female psychiatric out-patients. Br J Psychiatry 1997;171:69.
52. Coverdale JH, Aruffo JF. AIDS and family planning counseling of psychiatrically ill women in community mental health clinics. Community Ment Health J 1992;28:13.
53. Kim D, Kasper V, Noh S, Nam JH. Sexual and physical abuse among Korean female inpatients with schizophrenia. J Trauma Stress 2006;19:279.
54. Kumar P. Genetic counseling in family planning. Antiseptic 1968;65:831.
55. McDonald C, Murphy KC. The new genetics of schizophrenia. Psychiatr Clin North Am 2003;26:41.
56. Hodgkinson KA, Murphy J, O'Neill S, Brzustowicz L, Bassett AS. Genetic counseling for schizophrenia in the era of molecular genetics. Can J Psychiatry 2001; 46:123.
57. Haukka J, Suvisaari J, Lonnqvist J. Fertility of patients with schizophrenia, their siblings, and the general population: A cohort study from 1950 to 1959 in Finland. Am J Psychiatry 2003;160:460.
58. Currier GW, Simpson GM. Antipsychotic medications and fertility. Psychiatr Serv 1998;49:175.
59. Neumann NU, Frasch K. Olanzapine and pregnancy. 2 case reports. Nervenarzt 2001;72:876.
60. Tenyi T, Trixler M, Keresztes Z. Quetiapine and pregnancy. Am J Psychiatry 2002;159:674.
61. Dickson RA, Hogg L. Pregnancy of a patient treated with clozapine. Psychiatr Serv 1998;49:1081.
62. Lindamer LA, Buse DC, Auslander L, Unutzer J, Bartels SJ, Jeste DV. A comparison of gynecological variables and service use among older women with and without schizophrenia. Psychiatr Serv 2003;54: 902.
63. Nilsson E, Lichtenstein P, Cnattingius S, Murray RM, Hultman CM. Women with schizophrenia: Pregnancy outcome and infant death among their offspring. Schizophr Res 2002;58:221.
64. Trixler M, Gati A, Fekete S, Tenyi T. Use of antipsychotics in the management of schizophrenia during pregnancy. Drugs 2005;65;1193.
65. McKenna K, Koren G, Tetelbaum M, et al. Pregnancy outcome of women using atypical antipsychotic drugs: A prospective comparative study. J Clin Psychiatry 2005;66:444.
66. Usher K, Foster K, McNamara P. Antipsychotic drugs and pregnant or breastfeeding women: The issues for mental health nurses. J Psychiatr Ment Health Nurs 2005;12:713.
67. Hannerz H, Borga P, Borritz M. Life expectancies for individuals with psychiatric diagnoses. Public Health 2001;115:328.
68. Green AI, Canuso CM, Brenner MJ, Wojcik JD. Detection and management of comorbidity in patients with schizophrenia. Psychiatr Clin North Am 2003; 26:115.
69. Koran LM, Sox HC Jr, Marton KI, et al. Medical evaluation of psychiatric patients: I. Results in a state mental health system. Arch Gen Psychiatry 1989;46;733.
70. Dixon L, Postrado L, Delahanty J, et al. The association of medical comorbidity in schizophrenia with poor physical and mental health. J Nerv Ment Dis 1999;187:496.
71. Sokal J, Messias E, Dickerson F, et al. Comorbidity of medical illnesses among adults with serious mental illness who are receiving community psychiatric services, J Nerv Ment Dis 2004:192:421.
72. Joslassen RCD, Schindler V. Medical comorbidity and schizophrenia: Editor's introduction. Schizophr Bull 1996;22:411.
73. Daumit GL, Pronovost PJ, Anthony CB, Guallar E, Steinwachs DM, Ford DE. Adverse events during medical and surgical hospitalizations for persons with schizophrenia. Arch Gen Psychiatry 2006;63;267.
74. Harris EC, Barraclough B. Excess mortality of mental disorder. Br J Psychiatry 1998;173:11.
75. Mortensen PB, Juel K. Mortality and causes of death in first admitted schizophrenic patients. Br J Psychiatry 1993;163:183.
76. Brown S. Excess mortality of schizophrenia: A metaanalysis. Br J Psychiatry 1997;56:21.
77. Ruschena D, Mullen PE, Burgess P, et al. Sudden death in psychiatric patients. Br J Psychiatry 1998; 172:331.
78. Himelhoch S, Kreyenbuhl J, Lehman AL, Dixon L. Prevalence of chronic obstructive pulmonary disease among individuals with serious mental illness. Am J Psychiatry 2004;161:2317.
79. Daumit G, Goldberg R, Anthony C, et al. Physical activity patterns in adults with severe mental illness. J Nerv Ment Dis 2005;193:641.